Kyntra Bio (MEX:KYNB) Cyclically Adjusted Book per Share: MXN1,355.11 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:KYNB Kyntra Bio Inc MEX:KYNB
35 GF Score
Price MXN127.90
GF Value MXN98.73
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Kyntra Bio Cyclically Adjusted Book per Share?

Kyntra Bio MEX:KYNB 35 Cyclically Adjusted Book per Share is MXN1,355.11 as of Mar. 2026. GuruFocus rates MEX:KYNB with a GF Score™ of 35/100 and a GF Value™ of MXN98.73 (Modestly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Kyntra Bio's adjusted book value per share for the three months ended in Mar. 2026 was MXN-195.130. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN1,355.11 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Kyntra Bio's average Cyclically Adjusted Book Growth Rate was -12.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-20), Kyntra Bio's current stock price is MXN127.90. Kyntra Bio's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was MXN1,355.11. Kyntra Bio's Cyclically Adjusted PB Ratio of today is 0.09.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Kyntra Bio was 5.69. The lowest was 0.06. And the median was 0.13.


Kyntra Bio  (MEX:KYNB) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Kyntra Bio's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=127.90/1355.11
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Kyntra Bio was 5.69. The lowest was 0.06. And the median was 0.13.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Kyntra Bio Cyclically Adjusted Book per Share Related Terms


Kyntra Bio Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Kyntra Bio's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyntra Bio Cyclically Adjusted Book per Share Chart

Kyntra Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 1,571.63 2,028.45 1,368.87

Kyntra Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,854.99 1,713.63 1,443.38 1,368.87 1,355.11

MEX:KYNB vs TVGN, PSTV, GRDX: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Kyntra Bio's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyntra Bio Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kyntra Bio's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Kyntra Bio's Cyclically Adjusted PB Ratio falls into.


MEX:KYNB
35GF Score
Kyntra Bio Inc MEX:KYNB
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyntra Bio Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kyntra Bio's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-195.13/330.2130*330.2130
=-195.130

Current CPI (Mar. 2026) = 330.2130.

Kyntra Bio Quarterly Data

Book Value per Share CPI Adj_Book
201606 1,422.791 241.018 1,949.332
201609 1,366.782 241.428 1,869.415
201612 1,261.450 241.432 1,725.319
201703 962.281 243.801 1,303.349
201706 1,465.041 244.955 1,974.957
201709 3,168.819 246.819 4,239.484
201712 3,145.099 246.524 4,212.785
201803 2,719.521 249.554 3,598.504
201806 2,891.873 251.989 3,789.586
201809 2,597.487 252.439 3,397.747
201812 2,925.994 251.233 3,845.837
201903 2,754.702 254.202 3,578.408
201906 3,478.121 256.143 4,483.905
201909 3,364.556 256.759 4,327.093
201912 2,776.471 256.974 3,567.780
202003 3,022.379 258.115 3,866.605
202006 2,531.881 257.797 3,243.094
202009 2,744.875 260.280 3,482.378
202012 2,295.780 260.474 2,910.449
202103 2,059.096 264.877 2,567.004
202106 1,400.406 271.696 1,702.021
202109 1,806.617 274.310 2,174.796
202112 1,154.891 278.802 1,367.853
202203 843.219 287.504 968.480
202206 556.907 296.311 620.625
202209 140.842 296.808 156.693
202212 -110.998 296.797 -123.495
202303 -227.828 301.836 -249.247
202306 -446.379 305.109 -483.107
202309 -695.910 307.789 -746.611
202312 -877.136 306.746 -944.240
202403 -951.488 312.332 -1,005.961
202406 -1,059.884 314.175 -1,113.989
202409 -1,190.245 315.301 -1,246.537
202412 -1,165.491 315.605 -1,219.437
202503 -1,097.799 319.799 -1,133.548
202506 -1,038.293 322.561 -1,062.924
202509 -77.222 324.800 -78.509
202512 -133.643 324.054 -136.183
202603 -195.130 330.213 -195.130

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of MXN1,355.11 mean?
Kyntra Bio (MEX:KYNB) has a Cyclically Adjusted Book per Share of MXN1,355.11 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Kyntra Bio and its competitors.
Is Kyntra Bio's Cyclically Adjusted Book per Share too high?
Kyntra Bio's current Cyclically Adjusted Book per Share is MXN1,355.11. Overall, Kyntra Bio has a GF Score™ of 35/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's Cyclically Adjusted Book per Share compare to TVGN and PSTV?
Kyntra Bio's Cyclically Adjusted Book per Share of MXN1,355.11 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Kyntra Bio and its competitors. Kyntra Bio's current Cyclically Adjusted Book per Share is MXN1,355.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (MEX:KYNB) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN98.73, compared to a current price of MXN127.90 — trading 29.5% above its estimated fair value. The current Cyclically Adjusted Book per Share is MXN1,355.11. Kyntra Bio's overall GF Score™ is 35/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Kyntra Bio (MEX:KYNB), the current Cyclically Adjusted Book per Share is MXN1,355.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kyntra Bio (MEX:KYNB) Overvalued in 2026?

Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued. The current stock price of MXN127.90 is trading 29.5% above its estimated GF Value™ of MXN98.73. GuruFocus considers Kyntra Bio to be Modestly Overvalued.

Key valuation signals for MEX:KYNB:

  • Cyclically Adjusted Book per Share: MXN1,355.11
  • GF Value™: MXN98.73 vs. price of MXN127.90 (29.5% above fair value)
  • GF Score™: 35/100 with 8 warning signs

No single metric tells the full story. See the MEX:KYNB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kyntra Bio Business Description

Other Exchanges KYNB:USA0IL8:UK1FG0:Germany
Address 350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94133
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
35GF Score

Get the complete analysis for MEX:KYNB

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN127.90
Price
MXN98.73
GF Value